Search clinical trials for: formoterol Turbuhaler

Total 483 results

AstraZeneca

Completed

Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans (Titan)

Asthma

United States
AstraZeneca

Completed

Gemini Symbicort pMDI

Mild or Moderate Asthma
Dartmouth-Hitchcock Medical Center
Sunovion

Completed

Effect of Bronchodilation on Cycle vs Treadmill Exercise Endurance Time in COPD (ARFEET)

Chronic Obstructive Pulmonary Disease

United States
Sunovion

Completed

A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects

Asthma

United States
Western Sky Medical Research
AstraZeneca

Completed

Comparing Bronchodilation of Symbicort With and Without Valved Holding Chamber (Aerochamber Plus) (WSMR2)

Asthma

United States
University Medical Center Groningen

Unknown

Symptom-driven Maintenance and Reliever Treatment to Prevent Exacerbations in COPD

COPD

Netherlands
Sunovion

Completed

Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD

Chronic Obstructive Pulmonary Disease

United States
Franciscus Gasthuis
Teva Pharmaceuticals USA

Recruiting

Expertise Asthma COPD Program With Digital Support (EXACT@home)

Asthma

Netherlands
Imperial College London
AstraZeneca

Completed

Effect of Symbicort ® on GR in Sputum in COPD

Chronic Obstructive Lung Disease

United Kingdom
AstraZeneca

Completed

A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.

Asthma

United States
Pearl Therapeutics, Inc.

Completed

PT005 MDI Dose Ranging Versus Foradil Aerolizer Study

Chronic Obstructive Pulmonary Disease

United States
Novartis Pharmaceuticals
Pacira Pharmaceuticals, Inc

Completed

Formoterol Certihaler, Tiotropium HandiHaler and Tiotropium HandiHaler in Combination With Formoterol Certihaler in Patients With Stable Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

Switzerland
GlaxoSmithKline

Completed

Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs

Pulmonary Disease, Chronic Obstructive

Netherlands, United Kingdom
Bayer

Completed

Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator (DIGIT)

Raynaud Disease

Germany
AstraZeneca

Completed

Titratable Dosing in Moderate to Severe Asthmatics

Asthma
Novartis
Pacira Pharmaceuticals, Inc

Completed

A 3-week Study Investigating Patient Use and Functionality of Formoterol in a Novel Inhalation Device in Patients With Asthma

Asthma

United States
Johannes Gutenberg University Mainz
AstraZeneca

Completed

Change of Inspiratory Peak Flow in COPD

Chronic Obstructive Pulmonary Disease

Germany
Novartis

Completed

Study to Demonstrate Equivalence of Formoterol 12 and 24 µg Delivered Via Two Types of Single Dose Dry Powder Inhalers (Concept1 and Aerolizer)

Asthma

Germany
Organon and Co

Completed

Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate/Formoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED)

Asthma | Airway Inflammation
GlaxoSmithKline

Completed

A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Poland, Romania, Russian Federation, Ukraine, Bulgaria, Estonia, Mexico, Korea, Republic of, Slovakia, Greece, China, Italy, Hungary, Czechia
Stanford University
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...

Recruiting

ARrest RESpiraTory Failure From PNEUMONIA (ARREST)

Pneumonia | COVID-19 Pneumonia | Hypoxemia | Acute Respiratory Failure

United States
Organon and Co
Novartis

Completed

Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in Chronic Obstructive Pulmonary Disease (COPD) (Study P04230AM4)(COMPLETED)

Chronic Obstructive Pulmonary Disease (COPD)
Neutec Ar-Ge San ve Tic A.Ş

Completed

Tiotropium/Formoterol Via Discair® vs Tiotropium Monotherapy or Tiotropium + Formoterol Free Combination Treatment

COPD

Turkey
Imperial College London
AstraZeneca

Completed

Effect of Symbicort on GR Localisation in Asthma

Asthma

United Kingdom
Chiesi Farmaceutici S.p.A.

Withdrawn

Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children

Asthma in Children

Denmark
University of Copenhagen

Unknown

Beta2-adrenergic System and Training

Healthy
Novartis Pharmaceuticals

Withdrawn

Efficacy of Indacaterol 150 µg Versus Formoterol

Chronic Obstructive Pulmonary Disease (COPD)
Chiesi Farmaceutici S.p.A.

Completed

Formoterol-HFA 3-month Study in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

Poland
Organon and Co
Novartis

Completed

Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in COPD (Study P04229AM4)(COMPLETED)

Chronic Obstructive Pulmonary Disease (COPD)
Ache Laboratorios Farmaceuticos S.A.

Completed

Evaluation of the Efficacy and Safety of a Fixed-dose, Single-capsule Budesonide-formoterol Combination in Uncontrolled Asthma (Ach-ALN)

Asthma
Merck Sharp & Dohme LLC
Novartis; Integrated Therapeutics Group

Completed

Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272)

Pulmonary Disease, Chronic Obstructive
Chiesi Farmaceutici S.p.A.
University of Pisa; Fondazione Don Carlo Gnocchi Onlus; Universita degli Studi... and other collaborators

Completed

Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Italy
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia in Type 1 Diabetes.

Type 1 Diabetes

United States
AstraZeneca

Completed

An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients

Asthma | Airway Inflammation

United Kingdom
Shanghai Pulmonary Hospital, Shanghai, China

Unknown

Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis

Bronchiectasis | COPD

China
Pearl Therapeutics, Inc.

Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo

COPD
Gelb, Arthur F., M.D.

Recruiting

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

Asthma

United States
Orion Corporation, Orion Pharma

Completed

Inspiratory Flow Parameters and Handling of Easyhaler and Turbuhaler Inhalers (PIFECO)

Pulmonary Disease, Chronic Obstructive | Asthma

United Kingdom, Finland
Sunovion

Terminated

A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects

Chronic Obstructive Pulmonary Disease (COPD)

United States
Centre Hospitalier Intercommunal Creteil
AstraZeneca

Terminated

Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Moderate Asthma Exacerbation (ASTHMAFAST)

Asthma in Children

France
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma

Asthma
Research in Real-Life Ltd
Napp Pharmaceuticals Limited

Completed

A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down

Asthma

United Kingdom
GlaxoSmithKline

Completed

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, United States, Netherlands, Czechia
AstraZeneca

Completed

Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma

Asthma

Croatia
Chiesi Farmaceutici S.p.A.

Completed

Pharmacokinetic Clinical Study of CHF1535 NEXT DPI® Versus CHF1535 pMDI

Asthma

United Kingdom
AstraZeneca
Menarini Group

Completed

Effect of Aclidinium/Formoterol on Lung Hyperinflation, Exercise Capacity and Physical Activity in Moderate to Severe COPD Patients (ACTIVATE)

Pulmonary Disease, Chronic Obstructive

Germany, Hungary, Spain, Canada
University of Florida
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Dose-response of Inhaled Formoterol Using Methacholine Challenge as a Bioassay

Asthma

United States
Mylan Inc.
Theravance Biopharma

Completed

A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD

Chronic Obstructive Pulmonary Disease (COPD)

United States
AstraZeneca

Completed

Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler®

Chronic Obstructive Pulmonary Disease

Italy, Spain, Sweden
Dey

Completed

Study in Subjects Greater Than 40 Years of Age With COPD

Chronic Obstructive Pulmonary Disease

United States

3

Subscribe